A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT01194154

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01194154
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01194154. Randomized; single masking; primary purpose treatment. Start 2010-09-30 (actual); primary completion 2015-03-31 (actual). Results posted on 2016-06-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
Condition
Kidney Disease, Chronic
Intervention (Drug)
Methoxy polyethylene glycol-epoetin beta
Intervention (Drug)
Placebo
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01194154
Content hash
915dd314675402675e6f6e55594dd7f2b7e093957e4cd7022b36522967b7e959